BOSTON and ROLLE, Switzerland, Aug. 5, 2025 -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer. It will also support the potential development of a bespoke AI-powered predictive model aimed at optimizing outcomes for indivi
DONGGUAN, China, Aug 5, 2025 -- Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient enrollment in China for its Phase I clinical trial of FP008 , a first-in-class immunotherapy for solid tumors, at Zhejiang Cancer Hospital. The patient has completed the Dose Limiting Toxicity (DLT) observation period with a favorable safety profile. The trial aims to evaluate the safety and tolerability of FP008 in patients with advanced solid tumors. As the latest next generation of immuno-oncology (IO) app
GUANGZHOU, China, Aug. 5, 2025 -- Sunshine Lake Pharma Co., Ltd. (06887.HK) announced that the company will officially list on the Hong Kong Stock Exchange on August 7th. Through this integration, the company has effectively combined its expertise in drug R&D with the mature nationwide sales network resources of Sunshine Lake Pharma Co., Ltd. This forms an R&D-manufacturing-sales closed loop to accelerate global operations, thereby driving value reshaping and laying a more solid foundation for future sustainable development, including international expansion. This year, propell
BANGKOK, Aug. 4, 2025 -- Chugai Pharma Taiwan (CPT), a subsidiary of Chugai Pharmaceutical Co., Ltd. in Japan, has been recognized in both the Social Empowerment and Green Leadership categories at the Asia Responsible Enterprise Awards (AREA) 2025. These recognitions highlight the company's exceptional efforts in driving community impact and environmental sustainability through healthcare-focused innovation and compassion. In the Social Empowerment category, CPT was recognized for its heartfelt and impactful charitable initiatives. Through its annual charity cycling event, CPT not only
BANGKOK, Aug. 4, 2025 -- TSH Biopharm Corporation Ltd. has been recognized with dual honors at the Asia Responsible Enterprise Awards 2025, receiving accolades for the Green Leadership and Social Empowerment categories. The awards reflect the company's growing influence as a purpose-driven pharmaceutical firm that integrates sustainability and human well-being into its corporate DNA. TSH Biopharm's Green Leadership accolade celebrates its signature initiative, "Sowing with Heart," which redefines the connection between health and the environment. In a pioneering effort, the c
WUXI, China, Aug. 5, 2025 -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the Drug Product 3 ("DP3") facility at the Wuxi site has completed GMP release at the end of July, signifying the company's relentless pursuit of excellence in capacity expansion and business growth. In just 18 months, WuXi XDC has rapidly completed the advanced design, construction, equipment qualification, media fill and GMP release of the DP3
BANGKOK, Aug. 5, 2025 -- Chulalongkorn University's "High-Protein Jelly Pudding with Modified Texture for the Elderly with Swallowing Difficulties," developed by Asst. Prof. Dr. Varanya Techasukthavorn and a team from the Faculty of Allied Health Sciences, won a bronze medal in Geneva, along with a special award from Malaysia. Striking with banana and strawberry flavors, the jelly pudding is easy to consume and provides a high protein content of 7-8 grams per cup to strengthen muscles. It's suitable for the elderly, patients, and those who need additional protein. The team is prepar
SAN FRANCISCO and SUZHOU, China, Aug. 5, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to initiate a Phase 1 clinical trial of IBI3032, the company's novel oral GLP-1R agonist. IBI3032 is an orally administered small-molecule
PARIS, Aug. 5, 2025 -- A viral TikTok challenge known as "Burn Lines" or "Sunburn Tattoos" is gaining alarming traction among teenagers and young adults worldwide. The trend, which involves placing tape or stencils on the skin to intentionally burn patterned tan lines, has sparked widespread concern among global health experts. France's Minister of Health stated recently: "For a few seconds of buzz on social media, young people are destroying their skin cells for life. We only get one skin." LA ROCHE-POSAY REAFFIRMS ITS LONGSTANDING COMMITME
[ 메디채널 김갑성 기자 ] Investments Through 2030 to Catalyze Innovation in Maternal, Menstrual, Gynecological, and Sexual Health for Women Globally SEATTLE, Aug. 4, 2025 -- The Gates Foundation today announced a $2.5 billion commitment through 2030 to accelerate research and development (R&D) focused exclusively on women's health. It will support the advancement of more than 40 innovations in five critical, chronically underfunded areas—particularly those affecting women in low- and middle-income countries. "For too long, women have suffered from health conditions that are mi